In the third, final, and by most reckonings most inconsequential, national debate of the US presidential election, vice ...

Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax ...

Seven new clinical trial grants were awarded under the Orphan Product Grants Program during the fiscal year (FY) 2024, ...